Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C] Orvepitant in Healthy Males
NCT04387981Phase 1Completed
- Sponsor
- NeRRe Therapeutics
- Start
- Jun 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of orvepitant in chronic cough, sponsored by NeRRe Therapeutics. Primary endpoints: Percentage of radioactive dose recovered in urine and faeces and total percentage at 168 hours and Concentration of total radioactivity in blood and plasma at 168 hours. Started Jun 2020; status: completed.
02
Drugs
orvepitant
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT04387981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04387981.